Massivemarkets

GNPX

Genprex, Inc. Common Stock

Nasdaq · usd

$1.67-0.23 (-12.10%)
At close · 15-minute delayed
$1.71+0.04 (+2.47%)
As of 7:59:40 PM EST on Nov 17, 2026 · After hours

Genprex, Inc. Common Stock (GNPX) trades at $1.67 (-12.10%) as of 7:59:40 PM EST on Nov 17, 2026, -18.91% over the past month. Market cap is $1.56M, with 1.0 days to cover in short interest.

Stock performance

How Genprex, Inc. Common Stock (GNPX) stock has performed from one day to one year, with its 52-week range.

-8.20%
-$0.15 over 1D
$1.68$1.74$1.80$1.867:50 AM11:10 AM1:15 PM3:00 PM8:00 PM$1.68
1D
-12.08%
1W
-20.07%
1M
-18.91%
YTD
-95.66%
1Y
-97.94%
52-wk range
$1.66 – $93.94

Key statistics

Today's trading snapshot for GNPX: day range, open, previous close, volume and market cap.

Day range
$1.66 – $1.90
Open
$1.90
Prev close
$1.90
Volume
132.31K
Market cap
$1.56M
Shares out
819.71K

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Genprex, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
—
P/B
0.11
P/FCF
—
ROE
-111.5%
ROA
-96.3%
Debt/Equity
0.00
Div yield
0.00%

As of Nov 16, 2026

8-K filings

Material corporate events Genprex, Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Partnership or collaborationNov 5, 2026

    In collaboration with and pursuant to a sponsored research agreement with Meharry Medical College in Nashville, Tennessee, Genprex has been exploring aspects of REQORSA biology, including mitochondrial metabolism and molecular aging and their potential relationship to cancer.

  • Partnership or collaborationOct 28, 2026

    Genprex established a sponsored research collaboration with Meharry Medical College (Nashville, Tennessee) in 2024 to investigate aspects of REQORSA biology, including mitochondrial metabolism and molecular aging and their potential relationship to cancer.

  • Partnership or collaborationAug 18, 2026

    Genprex, Inc. issued a press release announcing it had entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization ("CDMO") to initiate the manufacturing scale-up of its diabetes gene therapy program. This strategic selection allows for the transition of the Company's therapeutic candidate from research-grade production to clinical and commercial-ready output.

  • On August 4, 2026, the Company was formally notified that the Panel determined that the Company has regained compliance with the Bid Price Requirement. The Panel further informed the Company that until December 7, 2026, which represents the full extent of the Panel's discretion in this matter with respect to the Bid Price Requirement, the Company must maintain a closing bid price at or above $1.00 for each trading day.

  • Partnership or collaborationAug 3, 2026

    Genprex, Inc. issued a press release announcing its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer ('NSCLC'). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.

Dividend history and stock splits

Genprex, Inc. Common Stock's recent dividend payments and stock splits.

Dividends

No recent dividends.

Splits

  • 1-for-22Jul 16, 2026
  • 1-for-50Oct 21, 2025
  • 1-for-40Feb 2, 2024

GNPX short interest

How heavily GNPX is shorted: shares short, days to cover and average daily volume.

Days to cover
1.0
Short interest
123.26K
Avg volume
170.47K

As of · reported to FINRA twice monthly.

GNPX news

The latest news and headlines about Genprex, Inc. Common Stock (GNPX).

Frequently asked questions

What is the Genprex, Inc. Common Stock (GNPX) stock price today?

Genprex, Inc. Common Stock (GNPX) is trading at $1.67 (-12.10% on the day) as of 7:59:40 PM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Genprex, Inc. Common Stock?

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and…

What is the short interest in GNPX?

As of Oct 30, 2026, GNPX has 123.26K shares short and 1.0 days to cover.

What exchange is GNPX listed on?

Genprex, Inc. Common Stock (GNPX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of GNPX with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a GNPX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.